Thomas Gwydir - Nephros Director
NEPH Stock | USD 2.27 0.06 2.71% |
Director
Mr. Thomas Gwydir is Director of the Company since 2019.
Tenure | 5 years |
Address | 380 Lackawanna Place, South Orange, NJ, United States, 07079 |
Phone | 201 343 5202 |
Web | https://www.nephros.com |
Nephros Management Efficiency
The company has return on total asset (ROA) of (0.0871) % which means that it has lost $0.0871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1827) %, meaning that it created substantial loss on money invested by shareholders. Nephros' management efficiency ratios could be used to measure how well Nephros manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Capital Employed is estimated to decrease to -0.17. The current Return On Assets is estimated to decrease to -0.14. As of now, Nephros' Other Current Assets are increasing as compared to previous years. The Nephros' current Intangible Assets is estimated to increase to about 1.1 M, while Total Assets are projected to decrease to under 7.5 M.Similar Executives
Showing other executives | DIRECTOR Age | ||
Maritza Montiel | AptarGroup | 69 | |
Robert Nelson | SharkNinja | 41 | |
Jinling Zhang | Viomi Technology ADR | 46 | |
De Liu | Viomi Technology ADR | 44 | |
Brian Carney | SharkNinja | 51 | |
Alan Jackson | SharkNinja | 73 | |
Giovanna Monnas | AptarGroup | 65 | |
Greg Colvin | SharkNinja | 54 | |
Jim McCrea | SharkNinja | N/A | |
Jesse Wu | AptarGroup | 62 | |
Eugene Davis | SharkNinja | 62 | |
Jesse Hahn | SharkNinja | N/A | |
Gilbert Garcia | SharkNinja | 53 | |
Alain Chevassus | AptarGroup | 72 | |
Joanne Smith | AptarGroup | 59 | |
Andreas Kramvis | AptarGroup | 68 | |
Peter Pfeiffer | AptarGroup | 66 | |
Gregory Colvin | SharkNinja | 57 | |
Ralf Wunderlich | AptarGroup | 55 | |
Sean Maher | SharkNinja | 44 | |
Weijiang Wu | Viomi Technology ADR | 40 |
Management Performance
Return On Equity | -0.18 | ||||
Return On Asset | -0.0871 |
Nephros Leadership Team
Elected by the shareholders, the Nephros' board of directors comprises two types of representatives: Nephros inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nephros. The board's role is to monitor Nephros' management team and ensure that shareholders' interests are well served. Nephros' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nephros' outside directors are responsible for providing unbiased perspectives on the board's policies.
Malcom Persen, Director | ||
Vashone Thomas, Regulatory, Quality | ||
Thomas Gwydir, Director | ||
Joleen Turner, VP Devel | ||
Paul Mieyal, Director | ||
Greg Lucas, President Systems | ||
Robert Banks, CEO President | ||
Alfred Vargas, Director Operations | ||
Daron Evans, CEO and President Acting CFO, Director and Member of Audit Committee | ||
Judy CFA, Chief Officer | ||
Judy Mazzini, Controller | ||
MS MBA, Inc Products | ||
Andrew Astor, CFO, CEO | ||
Alisa Lask, Director | ||
Matthew Rosenberg, Director | ||
Moshe Pinto, Director | ||
Arthur Amron, Independent Director | ||
Oliver Spandow, Director | ||
Brianne McGuire, Marketing Brand |
Nephros Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nephros a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.18 | ||||
Return On Asset | -0.0871 | ||||
Profit Margin | (0.11) % | ||||
Operating Margin | (0.20) % | ||||
Current Valuation | 20.83 M | ||||
Shares Outstanding | 10.54 M | ||||
Shares Owned By Insiders | 11.96 % | ||||
Shares Owned By Institutions | 40.22 % | ||||
Number Of Shares Shorted | 1.78 K | ||||
Price To Earning | (4.51) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Nephros Stock analysis
When running Nephros' price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Nephros' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.371 | Quarterly Revenue Growth 0.272 | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.